Experimental drug aims to improve breathing in lung sarcoidosis
NCT ID NCT07680166
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study tests an investigational drug called XTMAB-16 in people with pulmonary sarcoidosis, a condition that causes inflammation and scarring in the lungs. The trial aims to see if the drug can improve lung function (measured by forced vital capacity) and quality of life. Participants receive either XTMAB-16 or a placebo by infusion, and the study includes both dose-finding and efficacy evaluation phases.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- XTMAB-16
- What this could lead to
- If successful, this could provide a new treatment option to improve lung function and quality of life for people with pulmonary sarcoidosis.
- What could go wrong
- This is an early-phase trial combining dose-finding and initial efficacy testing, so results may not confirm benefit. Side effects are still being evaluated.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY SARCOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new infusion drug tame lung inflammation and cut steroid use?
- New drug aims to cut steroid use in lung sarcoidosis
- Sarcoidosis drug study halted after only 2 patients enrolled
- New pill could tame lung inflammation in sarcoidosis
- Could a poop pill tame inflammation? new trial tests FMT for arthritis and bowel disease
- Study reveals: sticking to sarcoidosis meds may improve outcomes